Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Top Owners Are Retail Investors With 58% Stake, While 26% Is Held by Institutions

Yahoo FinanceDec 12 11:23 ET

Press Release: Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Dow JonesDec 3 06:50 ET

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Eton PharmaceuticalDec 3 00:00 ET

H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $15

Moomoo NewsNov 26 06:34 ET · Ratings

Express News | Eton Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $15 From $11

ReutersNov 26 06:07 ET

Eton Pharmaceuticals Has Acquired The Us Rights To Amglidia (Glyburide Oral Suspension, Known As Glibenclamide In Europe) For Neonatal Diabetes Mellitus From AMMTeK, Potential US Marketing Application Submission Expected In 2026

BenzingaNov 25 06:52 ET